Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)

Completed

Conditions: Methicillin-Resistant Staphylococcus Aureus
Atopic Dermatitis
MRSA
Eczema Herpeticum

First Posted Date: 2009-01-14

Last Posted Date: 2014-04-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 65

Registration Number: NCT00822276

Locations: 🇺🇸
National Jewish Health, Denver, Colorado, United States
🇺🇸
University of California, San Diego, San Diego, California, United States

Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

Phase 2

Completed

Conditions: HIV Infections

Interventions: Biological: pGA2/JS7 DNA vaccine
Biological: Placebo
Biological: MVA/HIV62 vaccine

First Posted Date: 2009-01-12

Last Posted Date: 2022-08-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 299

Registration Number: NCT00820846

Locations: 🇺🇸
The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States
🇺🇸
Alabama CRS, Birmingham, Alabama, United States
🇺🇸
Bridge HIV CRS, San Francisco, California, United States

and more 9 locations

Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: Rifampicin
Drug: Isoniazid
Drug: Pyrazinamide
Drug: Kanamycin
Drug: Moxifloxacin

First Posted Date: 2009-01-01

Last Posted Date: 2019-12-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 19

Registration Number: NCT00816426

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Pusan National Unversity Hospital (PNUH), Busan, Korea, Republic of
🇰🇷
National Medical Center, Seoul, Korea, Republic of

Cytomegalovirus Cell-Mediated Immunity

Completed

Conditions: Cytomegalovirus Infections

First Posted Date: 2008-12-29

Last Posted Date: 2013-09-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 165

Registration Number: NCT00815165

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States
🇺🇸
Vanderbilt University - Pediatric - Infectious Diseases, Nashville, Tennessee, United States

Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma

Active, not recruiting

Conditions: Opportunistic Infections
Mycobacterium Tuberculosis
Nontuberculous Mycobacteria

First Posted Date: 2008-12-25

Last Posted Date: 2025-06-12

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 224

Registration Number: NCT00814827

Locations: 🇨🇳
National Taiwan University, Taiwan, China
🇹🇭
National Siriraj Hospital, Mahidol Universtiy, Bangkok, Thailand
🇹🇭
Ramathibodi Hospital, Mahidol Universtiy, Bangkok, Thailand

and more 2 locations

Treatment With hOKT3gamma1(Ala-Ala) in T1DM

Phase 2

Terminated

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: hOKT3gamma1(Ala-Ala)

First Posted Date: 2008-12-11

Last Posted Date: 2017-02-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT00806572

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Benaroya Research Institute, Seattle, Washington, United States
🇺🇸
Naomie Berrie Diabetes Center, Columbia University, New York, New York, United States

Normal Blood, Bone Marrow and Buccal Mucosa Protocol

Completed

Conditions: Non-atopic
Healthy
Normal
Atopic
Allergy

First Posted Date: 2008-12-10

Last Posted Date: 2023-01-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 119

Registration Number: NCT00806364

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children

Phase 1

Completed

Conditions: HIV Infections
Tuberculosis

Interventions: Drug: Efavirenz (EFV)
Drug: Rifampin-containing anti-TB therapy

First Posted Date: 2008-12-05

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 67

Registration Number: NCT00802802

Locations: 🇺🇬
MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda
🇮🇳
Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, Maharashtra, India
🇿🇼
Harare Family Care CRS, Harare, Zimbabwe

and more 4 locations

Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection

Phase 2

Completed

Conditions: Kidney Transplantation
Kidney Failure, Chronic

Interventions: Procedure: Kidney Transplantation
Procedure: Bone marrow transplantation
Biological: MEDI-507
Drug: cyclophosphamide
Biological: rituximab
Drug: Tacrolimus
Drug: corticosteroids
Radiation: thymic irradiation

First Posted Date: 2008-12-03

Last Posted Date: 2015-11-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 5

Registration Number: NCT00801632

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: rAd35
Biological: DNA Vaccine
Biological: rAd35 placebo
Biological: DNA Vaccine placebo
Biological: rAd5
Biological: rAd5 placebo

First Posted Date: 2008-12-03

Last Posted Date: 2021-10-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 192

Registration Number: NCT00801697

Locations: 🇺🇸
Columbia P&S CRS, New York, New York, United States
🇺🇸
New York Blood Center CRS, New York, New York, United States
🇺🇸
University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester, New York, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy